Mineralys Therapeutics, Inc.
MLYS Nasdaq
SEC CIK 1933414
Follow Mineralys Therapeutics
Weekly email: filings, results
Net income
−$57.3M
−55.2% vs same quarter last year
EPS, diluted
−$0.64
−23.1% vs same quarter last year
Operating cash flow
−$43.1M
−49.3% vs same quarter last year
Operating income
−$60.1M
−46.1% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$154.7M |
| FY24 | −$177.8M |
| FY23 | −$71.9M |
| FY22 | −$29.8M |
| FY21 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$142.4M |
| FY24 | −$166.4M |
| FY23 | −$81.2M |
| FY22 | - |
| FY21 | - |